Jade Biosciences JBIO
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$1.10M (6 inflow days, 14 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 44.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 15.17% to 16.31% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Franklin Resources | Mutual Fund | 2026/Q3 | +1,015,156 | 6.0% |
| FMR | Mutual Fund | 2026/Q3 | +683,211 | 15.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +521,850 | 5.2% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +472,204 | 1.9% |
| BNP Paribas Financial Markets SNC | Private Company | 2026/Q3 | +328,939 | 0.8% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +267,654 | 4.1% |
| Paradigm Biocapital Advisors LP | Hedge Fund | 2026/Q3 | +249,388 | 4.9% |
| Janus Henderson Group plc | Mutual Fund | 2026/Q3 | +3,167,593 | 9.9% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +2,792,045 | 4.4% |
| FMR | Mutual Fund | 2026/Q3 | +2,041,454 | 14.4% |
| Adage Capital Management, L.P. | Hedge Fund | 2026/Q3 | +1,910,812 | 3.0% |
| Polar Capital Holdings Plc | Mutual Fund | 2026/Q3 | +1,846,982 | 2.9% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,679,595 | 3.7% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +1,432,818 | 2.3% |
| Citadel Advisors LLC | Hedge Fund | 2026/Q3 | +792,185 | 1.5% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 24 Jun 2026 | Mark Eisner | Director | Other Derivative Acquisition | +47,675 | $21.81 | 47,675 |
| 8 Jun 2026 | Eric Dobmeier | Independent Chairperson | Other Derivative Acquisition | +34,843 | $15.22 | 34,843 |
| 8 Jun 2026 | Christopher Cain | Independent Director | Other Derivative Acquisition | +34,843 | $15.22 | 34,843 |
| 8 Jun 2026 | Erin Lavelle | Independent Director | Other Derivative Acquisition | +34,843 | $15.22 | 34,843 |
| 8 Jun 2026 | Lawrence Klein | Independent Director | Other Derivative Acquisition | +34,843 | $15.22 | 34,843 |
| 8 Jun 2026 | Peter Harwin | Other Derivative Acquisition | +34,843 | $15.22 | 34,843 | |
| 11 Feb 2026 | Tom Frohlich | Chief Executive Officer | Other Acquisition | +78,750 | – | 78,750 |
| 11 Feb 2026 | Tom Frohlich | Chief Executive Officer | Other Derivative Acquisition | +472,500 | $14.81 | 472,500 |
| 11 Feb 2026 | Bradford Dahms | Chief Financial Officer | Other Acquisition | +37,813 | – | 37,813 |
| 11 Feb 2026 | Bradford Dahms | Chief Financial Officer | Other Derivative Acquisition | +226,875 | $14.81 | 226,875 |
| 11 Feb 2026 | Andrew King | President of Research & Development | Other Acquisition | +41,250 | – | 41,250 |
| 11 Feb 2026 | Andrew King | President of Research & Development | Other Derivative Acquisition | +247,500 | $14.81 | 247,500 |
| 11 Feb 2026 | Elizabeth Bekiroglu | Other Acquisition | +28,125 | – | 28,125 | |
| 11 Feb 2026 | Elizabeth Bekiroglu | Other Derivative Acquisition | +168,750 | $14.81 | 168,750 | |
| 5 Oct 2025 | Fairmount Funds Management LLC | Private Acquisition | +1,333,126 | $9.14 | 4,553,494 | |
| 5 Oct 2025 | Fairmount Funds Management LLC | Other Derivative Acquisition | +855,047 | $0.00 | 855,047 | |
| 13 Jul 2025 | Bradford Dahms | Chief Financial Officer | Other Derivative Acquisition | +526,000 | $9.00 | 526,000 |
| 24 Jun 2025 | Atlas Venture Advisors, Inc. | Intent to Sell (Form 144) | -28,977 | $10.48 | – | |
| 24 Jun 2025 | Atlas Venture Advisors, Inc. | Intent to Sell (Form 144) | -235 | $10.48 | – | |
| 23 Jun 2025 | Atlas Venture Advisors, Inc. | Intent to Sell (Form 144) | -16,132 | $9.87 | – |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 10,374,791 | 16.3% | 14.1 |
| 15 Oct 2026 | 11,210,801 | 17.6% | 10.9 |
| 30 Sep 2026 | 12,119,108 | 19.1% | 11.3 |
| 15 Sep 2026 | 10,982,905 | 17.3% | 11.8 |
| 31 Aug 2026 | 9,994,410 | 15.7% | 16.5 |
| 14 Aug 2026 | 9,650,429 | 15.2% | 10.2 |
No comments yet — be the first to weigh in on JBIO.
Sign in to join the discussion.